These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17062678)

  • 1. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.
    Zhang X; Shu XO; Cai Q; Ruan Z; Gao YT; Zheng W
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6037-42. PubMed ID: 17062678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
    Eroglu A; Ulu A; Cam R; Akar N
    J BUON; 2006; 11(4):481-4. PubMed ID: 17309181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
    Lei H; Hemminki K; Johansson R; Altieri A; Enquist K; Henriksson R; Lenner P; Försti A
    Breast Cancer Res Treat; 2008 May; 109(1):165-75. PubMed ID: 17616807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
    Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
    Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
    Błasiak J; Smolarz B
    Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.
    Yagmurdur MC; Atac FB; Tutar NU; Verdi H; Isiklar I; Ozdemir BH; Ozbek N; Karakayali H; Haberal M
    Int Surg; 2008; 93(3):163-8. PubMed ID: 18828272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
    Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.
    Palmirotta R; Ferroni P; Savonarola A; Martini F; Ciatti F; Laudisi A; Sini V; Del Monte G; Guadagni F; Roselli M
    Thromb Res; 2009 Sep; 124(4):403-8. PubMed ID: 19351570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province].
    Liu SQ; Xue YM; Yang GC; He FY; Zhao XS
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Aug; 24(8):904-7. PubMed ID: 15321757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
    Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
    Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of cyclin D1 genotype with breast cancer risk and survival.
    Shu XO; Moore DB; Cai Q; Cheng J; Wen W; Pierce L; Cai H; Gao YT; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):91-7. PubMed ID: 15668481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.
    Funk M; Endler G; Exner M; Marculescu R; Endler L; Abrahamian H; Mauler H; Grimm A; Raith M; Mannhalter C; Prager R; Irsigler K; Wagner OF
    Wien Klin Wochenschr; 2005 Oct; 117(19-20):707-10. PubMed ID: 16416371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients.
    Corsetti JP; Ryan D; Moss AJ; Rainwater DL; Zareba W; Sparks CE
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):548-54. PubMed ID: 18096824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers of the uPA system and common prognostic factors in breast cancer.
    Minisini AM; Fabbro D; Di Loreto C; Pestrin M; Russo S; Cardellino GG; Andreetta C; Damante G; Puglisi F
    Am J Clin Pathol; 2007 Jul; 128(1):112-7. PubMed ID: 17580278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of PAI-1 promoter 4G/5G polymorphism in healthy Chinese and functional characterization using a luciferase reporter vector.
    Ding Z; Pan JQ
    Ann Hematol; 2005 Mar; 84(3):183-7. PubMed ID: 15309528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels.
    Kathiresan S; Gabriel SB; Yang Q; Lochner AL; Larson MG; Levy D; Tofler GH; Hirschhorn JN; O'Donnell CJ
    Circulation; 2005 Sep; 112(12):1728-35. PubMed ID: 16172282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms at FCER1B and PAI-1 and asthma susceptibility.
    Hizawa N; Maeda Y; Konno S; Fukui Y; Takahashi D; Nishimura M
    Clin Exp Allergy; 2006 Jul; 36(7):872-6. PubMed ID: 16839401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS.
    Tsangaris I; Tsantes A; Bonovas S; Lignos M; Kopterides P; Gialeraki A; Rapti E; Orfanos S; Dimopoulou I; Travlou A; Armaganidis A
    Thromb Res; 2009 Apr; 123(6):832-6. PubMed ID: 18804848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer.
    Offersen BV; Riisbro R; Knoop A; Brünner N; Overgaard J;
    Acta Oncol; 2007; 46(6):782-91. PubMed ID: 17653901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
    Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
    Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.